PMC:7558914 / 1634-1811
Annnotations
LitCovid_Glycan-Motif-Structure
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T3 | 29-36 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
T4 | 29-36 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
41 | 51-59 | Species | denotes | patients | Tax:9606 |
42 | 86-94 | Species | denotes | patients | Tax:9606 |
60 | 29-36 | Chemical | denotes | heparin | MESH:D006493 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T14 | 0-177 | Sentence | denotes | Higher prophylactic doses of heparin for high-risk patients and therapeutic doses for patients in critical condition were included in 53.3% and 33.3% of protocols, respectively. |